Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Supportive and palliative care

1554MO - Perspectives of patients with metastatic breast cancer on exercise interventions: Results from a survey in five European countries


10 Sep 2022


Mini Oral session: Supportive and palliative care


Supportive and Palliative Care

Tumour Site


Maike Sweegers


Annals of Oncology (2022) 33 (suppl_7): S713-S742. 10.1016/annonc/annonc1075


M. Sweegers1, J. Depenbusch2, N. Aaronson3, Y. Wengström4, M. Backman4, N. Gunasekara5, D. Clauss5, M. Pelaez6, M. Lachowicz7, A.M. May8, K. Steindorf2, M. Stuiver1

Author affiliations

  • 1 Center For Quality Of Life And Department Of Psychosocial Research And Epidemiology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 2 Division Of Physical Activity, Prevention And Cancer, DKFZ - German Cancer Research Center, 69120 - Heidelberg/DE
  • 3 Division Of Psychosocial Research & Epidemiology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 4 Departement Of Neurobiology, Care Sciences And Society, Division Of Nursing, Karolinska Institute, 141 83 - Huddlinge/SE
  • 5 Department Of Molecular And Cellular Sports Medicine, German Sport University Cologne, 50933 - Cologne/DE
  • 6 Physical Exercise Research, Onkologikoa Fundazioa, 20014 - Donostia/ES
  • 7 Department Of Oncology And Radiotherapy, Medical University of Gdansk, 80-210 - Gdansk/PL
  • 8 Julius Center For Health Sciences And Primary Care, University Medical Center Utrecht, 3584 CX - Utrecht/NL


Login to access the resources on OncologyPRO.

Abstract 1554MO


To successfully implement exercise programs for patients with metastatic breast cancer, services and education on expected benefits and how to overcome barriers should be aligned with patient preferences, values, and goals. Hence, gaining insight into patients’ perspectives on exercise and exercise programming is crucial.


In this cross-sectional survey, we recruited patients from 13 centers in the Netherlands, Germany, Poland, Spain, and Sweden. We collected data on patients’ knowledge about exercise and outcome expectations. We identified barriers to and facilitators for participation in exercise programs, and patients’ preferences for content and modes of exercise delivery.


420 patients completed the survey. Respondents were on average 56 years old and 70% had bone metastases. 65% reported having sufficient skills to engage in aerobic exercise, but only 34% did so for resistance exercise. Overall, respondents expected exercise to have multiple physical benefits, but a few expected exercise to worsen their pain (5%) or fatigue (4%). Feeling too tired (22%) and/or weak (23%) and not having access to an exercise program for cancer patients (26%) were the most prominent barriers. Facilitators for exercising regularly were previous positive physical (70%) and emotional (66%) experiences from exercising, and getting personalized advice from a physiotherapist (60%). Patients were most interested in walking and preferred exercising at a public gym, physiotherapy practice or outdoors, with inter-country differences. 56% did not know whether their insurance company reimburses exercise programs and only 9% would be willing to pay > €50 per month to participate.


A large proportion of patients with metastatic breast cancer reported not having the necessary skills to engage in regular exercise as recommended by current exercise guidelines for people with cancer. Patients may benefit from personalized advice and training facilities where they receive instructions and can practice safe and effective exercises. When implementing exercise interventions for patients with metastatic breast cancer, attention should be given to reimbursement and willingness-to-pay.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital.


European Union’s Horizon 2020 research and innovation programme.


A.M. May: Financial Interests, Institutional, Advisory Role: COMPASS. K. Steindorf: Financial Interests, Personal, Expert Testimony, < €5,000: Institut National contre le cancer (INCA), Paris, France; Financial Interests, Personal, Expert Testimony, Member of Data Monitoring Board; < €1,000: Swiss Group for Clinical Research (SAAK), Switzerland; Financial Interests, Personal, Invited Speaker, < €1,000: Adviva, Heidelberg, Germany, Pierre Fabre, Freiburg, Germany, Takeda, Breast Cancer Care Center, Unna, Germany, Audi Health Care Insurance, Ingolstadt, Germany, University of Mainz, Germany; Financial Interests, Personal, Invited Speaker, Lecturer fee in Master Course, < €2,000: University of Heidelberg, Germany; Financial Interests, Personal, Expert Testimony, compensation of travel costs, no further fees: German Research Foundation (DFG), Bonn, Germany; Financial Interests, Personal, Expert Testimony, < €1,000: University of Vienna, Vienna, Austria. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.